Search

Your search keyword '"Simonsson B"' showing total 672 results
Start Over Author "Simonsson B"
672 results on '"Simonsson B"'

2. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Author

Hoffmann, V S, Baccarani, M, Hasford, J, Castagnetti, F, Di Raimondo, F, Casado, L F, Turkina, A, Zackova, D, Ossenkoppele, G, Zaritskey, A, Höglund, M, Simonsson, B, Indrak, K, Sninska, Z, Sacha, T, Clark, R, Bogdanovic, A, Hellmann, A, Griskevicius, L, Schubert-Fritschle, G, Sertic, D, Guilhot, J, Lejniece, S, Zupan, I, Burgstaller, S, Koskenvesa, P, Everaus, H, Costeas, P, Lindoerfer, D, Rosti, G, Saussele, S, Hochhaus, A, and Hehlmann, R

Published
2017
Full Text
View/download PDF

4. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Author

Hoffmann, V S, Baccarani, M, Hasford, J, Lindoerfer, D, Burgstaller, S, Sertic, D, Costeas, P, Mayer, J, Indrak, K, Everaus, H, Koskenvesa, P, Guilhot, J, Schubert-Fritschle, G, Castagnetti, F, Di Raimondo, F, Lejniece, S, Griskevicius, L, Thielen, N, Sacha, T, Hellmann, A, Turkina, A G, Zaritskey, A, Bogdanovic, A, Sninska, Z, Zupan, I, Steegmann, J-L, Simonsson, B, Clark, R E, Covelli, A, Guidi, G, and Hehlmann, R

Published
2015
Full Text
View/download PDF

6. Use of Roquinimex in the Myeloid Leukemias

Author

Rowe, J. M., Nilsson, B. I., Simonsson, B., Hiddemann, W., editor, Plunkett, W., editor, Büchner, T., editor, Ritter, J., editor, Wörmann, B., editor, Keating, M. J., editor, and Creutzig, U., editor

Published
1996
Full Text
View/download PDF

10. Alcohol consumption and self-rated health among older people : population-based study in Sweden

Author

Lindström, J., Hellström, Charlotta, Simonsson, B., Molarius, A., Lindström, J., Hellström, Charlotta, Simonsson, B., and Molarius, A.

Abstract

OBJECTIVE: To analyse alcohol consumption and its association with self-rated health among a representative sample of older people in mid-Sweden. BACKGROUND: Over the past decades, alcohol consumption has increased in the older population in Sweden, but few studies have investigated the association between alcohol consumption and self-rated health in this group. The aim was therefore to investigate alcohol consumption and self-rated health among older Swedes. METHODS: The study is based on a cross-sectional study of 11,716 men and women, 65 years and over, answering a survey questionnaire sent to a random population sample in mid-Sweden in 2012. We assessed alcohol consumption with AUDIT-C and its association with self-rated health using logistic regression analysis, adjusting for age, economic situation, educational level, BMI, physical activity, social support and medication use. RESULTS: Men (83%) were more prone to drink alcohol compared to women (71%). The prevalence of risk drinking was about 2% for both genders. Alcohol consumption declined with age. Moderate consumption of alcohol was associated with lower probability of poor self-rated health compared to non-drinking with an adjusted odds ratio 0.64 (95% confidence interval: 0.54-0.76) for men and 0.68 (0.59-0.79) for women. CONCLUSION: Since the study was cross-sectional the direction of the association could not be determined, and the results should not be interpreted as an argument for promoting alcohol consumption among older people.

Published
2020
Full Text
View/download PDF

21. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Author

Hehlmann, R, Cortes, J, Zyczynski, T, Gambacorti-Passerini, C, Goldberg, S, Mauro, M, Michallet, M, Simonsson, B, Williams, L, Gajavelli, S, Degutis, I, Sen, G, Paquette, R, Hehlmann, Rüdiger, Cortes, Jorge E., Zyczynski, Teresa, Gambacorti-Passerini, Carlo, Goldberg, Stuart L., Mauro, Michael J., Michallet, Mauricette, Simonsson, Bengt, Williams, Loretta A., Gajavelli, Srikanth, DeGutis, Irene, Sen, Ginny P., Paquette, Ron L., Hehlmann, R, Cortes, J, Zyczynski, T, Gambacorti-Passerini, C, Goldberg, S, Mauro, M, Michallet, M, Simonsson, B, Williams, L, Gajavelli, S, Degutis, I, Sen, G, Paquette, R, Hehlmann, Rüdiger, Cortes, Jorge E., Zyczynski, Teresa, Gambacorti-Passerini, Carlo, Goldberg, Stuart L., Mauro, Michael J., Michallet, Mauricette, Simonsson, Bengt, Williams, Loretta A., Gajavelli, Srikanth, DeGutis, Irene, Sen, Ginny P., and Paquette, Ron L.

Abstract

SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor (TKI) use and management patterns in patients with chronic phase-chronic myeloid leukemia in the US and Europe in routine clinical practice. Herein we describe interruptions, discontinuations and switching of TKI therapy during the initial 2 years of treatment among 1121 patients prospectively enrolled between October 1, 2010 and March 7, 2017. Patient characteristics were broadly similar between the imatinib (n = 370), dasatinib (n = 376), and nilotinib (n = 375) cohorts. Treatment interruptions occurred in 16.4% (year 1) and 4.0% (year 2) of patients, mainly attributed to hematologic intolerances. Treatment discontinuations occurred in 21.8% (year 1) and 10.2% (year 2) of patients, with the highest rate within the first 3 months for intolerance. Switching of TKI was seen in 17.8% (year 1) and 9.5% (year 2) of patients. Significant associations were found between TKI switching and female gender (year 1), age ≥65 years at diagnosis (year 2) and treatment with imatinib (year 2). Intolerance was the most common reason given for patients discontinuing and for switching TKI therapy; however resistance was also cited. Lack of response monitoring in routine clinical practice may have resulted in lower identification of resistance in this dataset. Data from SIMPLICITY suggest that, in routine clinical practice, intolerance and resistance to TKIs influence decisions to change treatment. Changes in TKI therapy are frequent, with nearly a third of patients discontinuing their first-line TKI.

Published
2019

33. Physical mobility, physical activity, and obesity among elderly : findings from a large population-based Swedish survey

Author

Asp, Margareta, Simonsson, B., Peter, Larm, Molarius, A., Asp, Margareta, Simonsson, B., Peter, Larm, and Molarius, A.

Abstract

Objective To examine how physical activity and physical mobility are related to obesity in the elderly. Study design A cross-sectional study of 2558 men and women aged 65 years and older who participated in a population survey in 2012 was conducted in mid-Sweden with an overall response rate of 67%. Methods Obesity (body mass index ≥30 kg/m2) was based on self-reported weight and height, and physical activity and physical mobility on questionnaire data. Chi-squared test and multiple logistic regressions were used as statistical analyses. Results The overall prevalence of obesity was 19% in women and 15% in men and decreased after the age of 75 years. A strong association between both physical activity and obesity, and physical mobility and obesity was found. The odds for obesity were higher for impaired physical mobility (odds ratio [OR] 2.83, 95% confidence interval [CI] 2.14–3.75) than for physical inactivity (OR 1.63, 95% CI 1.28–2.08) when adjusted for gender, age, socio-economic status and fruit and vegetable intake. However, physical activity was associated with obesity only among elderly with physical mobility but not among those with impaired physical mobility. Conclusion It is important to focus on making it easier for elderly with physical mobility to become or stay physically active, whereas elderly with impaired physical mobility have a higher prevalence of obesity irrespective of physical activity.

Published
2017
Full Text
View/download PDF

36. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Author

Goldberg, S, Cortes, J, Gambacorti-Passerini, C, Hehlmann, R, Khoury, H, Michallet, M, Paquette, R, Simonsson, B, Zyczynski, T, Foreman, A, Abruzzese, E, Andorsky, D, Beeker, A, Cony-Makhoul, P, Hansen, R, Lomaia, E, Olavarria, E, Mauro, M, Goldberg, SL, Cortes, JE, Khoury, HJ, Paquette, RL, Mauro, MJ, Goldberg, S, Cortes, J, Gambacorti-Passerini, C, Hehlmann, R, Khoury, H, Michallet, M, Paquette, R, Simonsson, B, Zyczynski, T, Foreman, A, Abruzzese, E, Andorsky, D, Beeker, A, Cony-Makhoul, P, Hansen, R, Lomaia, E, Olavarria, E, Mauro, M, Goldberg, SL, Cortes, JE, Khoury, HJ, Paquette, RL, and Mauro, MJ

Abstract

Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n = 416), dasatinib (n = 418) or nilotinib (n = 408) in the US and 6 European countries in routine clinical practice. Twelve-month follow-up data of 1242 prospective patients (enrolled October 01 2010-September 02 2015) are reported. 81% of patients had baseline comorbidities. Treatment selection was based on perceived efficacy over patient comorbidity profile. There was a predominance of imatinib-treated patients enrolled earlier in the study, with subsequent shift toward dasatinib- and nilotinib-treated patients by 2013/2014. Monitoring for either CyR/MR improved over time and was documented for 36%, 82%, and 95% of patients by 3, 6, and 12 months, respectively; 5% had no documentation of CyR/MR monitoring during the first year of therapy. Documentation of MR/CyR testing was higher in Europe than the US (P <.001) and at academic versus community practices (P =.001). Age <65 years, patients being followed at sites within Europe, those followed at academic centers and patients no longer on first-line therapy were more likely to be monitored by 12 months. SIMPLICITY demonstrates that the NCCN and ELN recommendations on response monitoring have not been consistently translated into routine clinical practice. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted.

Published
2017

38. The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases

Author

Bonifazi, F, De Vivo, A, Rosti, G, Guilhot, F, Guilhot, J, Trabacchi, E, Hehlmann, R, Hochhaus, A, Shepherd, P, Steegmann, J, Kluin-Nelemans, H, Thaler, J, Simonsson, B, Louwagie, A, Reiffers, J, Mahon, F, Montefusco, E, Alimena, G, Hasford, J, Richards, S, Saglio, G, Testoni, N, Martinelli, G, Tura, S, and Baccarani, M

Published
2016

40. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

Author

Baccarani M, Cortes J, PANE, FABRIZIO, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European L.e.u.k.e.m.i.a.N.e.t., Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, Baccarani, M, Cortes, J, Pane, Fabrizio, Niederwieser, D, Saglio, G, Apperley, J, Cervantes, F, Deininger, M, Gratwohl, A, Guilhot, F, Hochhaus, A, Horowitz, M, Hughes, T, Kantarjian, H, Larson, R, Radich, J, Simonsson, B, Silver, Rt, Goldman, J, Hehlmann, R, and European, L. e. u. k. e. m. i. a. N. e. t.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Time Factors, allogeneic hematopoietic stem cell transplantation, chronic myeloid leukemia, cytogenetics, human, outcome assessment, priority journal, review, surgical risk, treatment failure, treatment outcome, treatment response, Dasatinib, Antineoplastic Agents, Review Article, Drug Administration Schedule, Piperazines, European LeukemiaNet, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Transplantation, Homologous, Treatment Failure, Protein Kinase Inhibitors, Gene Expression Regulation, Leukemic, business.industry, alpha interferon, alpha2b interferon, hydroxyurea, imatinib, nilotinib, peginterferon, protein tyrosine kinase inhibitor, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Imatinib, medicine.disease, Europe, Transplantation, Thiazoles, Pyrimidines, Treatment Outcome, Imatinib mesylate, Nilotinib, Benzamides, Immunology, Imatinib Mesylate, Drug Monitoring, business, medicine.drug, Chronic myelogenous leukemia
Abstract

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. Results Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. Conclusion Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.

Published
2009

41. Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Author

Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade Brittinger, C., Lacroix, A., Jarzab, B., Sorbye, H., Torpy, D. J., Stepan, V., Schteingart, D. E., Arlt, W., Kroiss, M., Leboulleux, S., Sperone, P., Sundin, A., Hermsen, I., Hahner, S., Willenberg, H. S., Tabarin, A., Quinkler, M., De La Fouchardiere, C., Schlumberger, M., Mantero, F., Weismann, D., Beuschlein, F., Gelderblom, H., Wilmink, H., Sender, M., Edgerly, M., Kenn, W., Fojo, T., Muller, H. H., Skogseid, B., Haaf, M., Johanssen, S., Koschker, A. C., Laubner, K., Sbiera, S., Schiemann, J., Wortmann, S., Haase, M., Schott, M., Möhlig, M., Zopf, K., Reisch, N., Betz, M., Reincke, M., Isermann, B., Bornstein, S., Fottner, C., Bose, A., Petersenn, S., Leitolf, H., Klose, S., Wolf, H., Chougnet, C., More, J., Nunes, M. L., Droz, J. P., Nicolli, P., Chabre, O., Clergeot, A., Schillo, F., Penfornis, A., Do Cao, C., Goldwasser, F., Rodien, P., Ferrero, A., Perotti, P., Cicala Mv, Anna P., Della Casa, S., Mannelli, M., Piccini, V., Dercksen, M. W., Romijn, J. A., Ouwerkerk, J., Devries, J. H., Eriksson, B., Janson, E. T., Granberg, D., Oberg, K., Ahlman, H., Garkavij, M., Wall, N., Falkmer, U., Hammer, G., Olney, H. J., Bourdeau, I., Bourque, L., Szpak Ulczok, S., Jarzab, M., Holte, H., Fossa, A., Ploner, F., Mansmann, U., Schmoll, H. J., Simonsson, B., Toscano, Vincenzo, Petersenn, Stephan (Beitragende*r), CCA -Cancer Center Amsterdam, Oncology, Other departments, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, General Internal Medicine, and Endocrinology

Subjects
Adult, Male, adrenal tumor, medicine.medical_specialty, Medizin, Kaplan-Meier Estimate, Gastroenterology, Disease-Free Survival, Streptozocin, Young Adult, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Adrenocortical Carcinoma, Medicine, Adrenocortical carcinoma, Humans, Mitotane, Adverse effect, Etoposide, Aged, Intention-to-treat analysis, business.industry, Medicine (all), Hazard ratio, Combination chemotherapy, General Medicine, Middle Aged, medicine.disease, Adrenal Cortex Neoplasms, Surgery, Intention to Treat Analysis, Regimen, Doxorubicin, Cisplatin, Female, Quality of Life, business, medicine.drug
Abstract

A b s t r ac t Background Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. Methods We randomly assigned 304 patients with advanced adrenocortical carcinoma to re ceive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. Results For first-line therapy, patients in the EDP–mitotane group had a significantly higher response rate than those in the streptozocin–mitotane group (23.2% vs. 9.2%, P

Published
2012
Full Text
View/download PDF

44. ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY

Author

Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., Costeas, P., Mayer, J., Indrak, K., Everaus, H., Koskenvesa, P., Guilhot, J., Schubert-Fritschle, G., Castagnetti, F., Di Raimondo, F., Lejniece, S., Griskevicius, L., Thielen, N., Sacha, T., Hellmann, A., Turkina, A., Zaritskey, A., Andrija Bogdanovic, Sninska, Z., Zupan, I., Steegmann, J. -L, Simonsson, B., Clark, R., and Hehlmann, R.

Published
2015

45. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Author

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Moiraghi B, Perez M, Greil R, Valent P, Bosly A, Martiat P, Noens L, André M, Verhoef G, Conchon M, Souza C, Nonino A, Hungria V, Zanichelli MA, Colturato V, Forrest D, Lipton JH, Savoie ML, Delage R, Lalancette M, Quintero G, Gomez M, Klamova H, Faber E, Bjerrum OW, Fredriksen H, Vestergaard H, Marcher C, Kamel H, Elzawam H, Porkka K, Remes K, Reiffers J, Guilhot F, Facon T, Tulliez M, Guerci Bresler AP, Nicolini FE, Charbonnier A, Rea D, Johnson Ansah A, Legros L, Harousseau JL, Rigal Huguet F, Escoffre M, Gardembas M, Guyotat D, Cahn JY, Gattermann N, Ottmann O, Niederwieser D, Stegelmann F, Schafhausen P, Brümmendorf T, Duyster J, Blumenstengel K, Scheid C, Kneba M, Kwong YL, Masszi T, Petrini M, Alimena G, Di Raimondo F, Rosti G, Rotoli B, Pungolino E, Amadori S, Abruzzese E, Fioritoni G, Lauria F, Bosi A, Martelli M, Rambaldi A, Ferrara F, Nobile F, Gobbi M, Carella AM, Orlandi EM, Leoni P, Tiribelli M, Levis A, Imamura M, Takahashi N, Tsukamoto N, Chiba S, Nagai T, Okamoto S, Miura O, Kurokawa M, Ohnishi K, Toba K, Nakao S, Tomita A, Miyamura K, Hino M, Maeda Y, Kimura A, Kawaguchi T, Miyazaki Y, Nakaseko C, Jinnai I, Matsuda A, Matsumura I, Ishikawa J, Ohyashiki K, Okada M, Usuki K, Kobayashi Y, Ohishi K, Imai K, Miyawaki S, Kanda Y, Park SY, Kim HJ, Sohn SK, Lee KH, Jung CW, Ong TC, Gómez Almaguer D, Kassack J, Ossenkoppele GJ, Gedde Dahl T, Hjorth Hansen H, Jedrzejczak W, Dmoszynska A, Starzak Dwozdz J, Holowiecki J, Kyrcz Krzemieñ S, Kuliczkowski K, Zaritsky A, Turkina A, Pospelova T, Goh YT, Koh LP, Demitrovicova L, Mistrik M, Ruff P, Louw V, Dreosti LM, Novitzky N, Cohen G, Cervantes F, Cañizo C, de Paz R, del Castillo S, Perez Encinas M, Sanz Alonso M, Marin F, Pérez López R, Hernandez Boluda J, Echeveste Gutierrez MA, Odriozola J, Herrera P, Steegman JL, Conde E, Lopez P, Giraldo P, Boque C, Heredia B, Font AJ, Rodriguez RF, Rodriguez MJ, Batlle J, Stenke L, Lehmann S, Wadenvik H, Simonsson B, Markevärn B, Själander A, Richter J, Bjoreman M, Eriksson KM, Chalandon Y, Shih LY, Yao M, Wang MC, Jootar S, Bunworasate U, Ulkü B, Haznedar R, Undar B, Sahin B, Marin D, Smith G, Byrne J, Holyoake T, Kalaycio M, Akard L, Heaney M, Al Janadi A, Goldberg S, Powell B, Harker WG, Shea T, Gingrich R, Glass J, Paquette R, Siegrist C, Woodson M, Fehrenbacher L, Koh H, Flinn I, Arrowsmith E, Ervin T, Guerra M, Wallach H, Berry W, Burke J, Edenfield W, Guzley G, Davis J, Richards D, Schlossman D, Kolibaba K, Alemany C, Savin M, Robbins G, Lopez J, Goldman JM, Camm J, Schiffer CA, Sargent D.J., PANE, FABRIZIO, Saglio, G, Kim, Dw, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, Re, Hochhaus, A, Hughes, Tp, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Larson, Ra, Kantarjian, Hm, Moiraghi, B, Perez, M, Greil, R, Valent, P, Bosly, A, Martiat, P, Noens, L, André, M, Verhoef, G, Conchon, M, Souza, C, Nonino, A, Hungria, V, Zanichelli, Ma, Colturato, V, Forrest, D, Lipton, Jh, Savoie, Ml, Delage, R, Lalancette, M, Quintero, G, Gomez, M, Klamova, H, Faber, E, Bjerrum, Ow, Fredriksen, H, Vestergaard, H, Marcher, C, Kamel, H, Elzawam, H, Porkka, K, Remes, K, Reiffers, J, Guilhot, F, Facon, T, Tulliez, M, Guerci Bresler, Ap, Nicolini, Fe, Charbonnier, A, Rea, D, Johnson Ansah, A, Legros, L, Harousseau, Jl, Rigal Huguet, F, Escoffre, M, Gardembas, M, Guyotat, D, Cahn, Jy, Gattermann, N, Ottmann, O, Niederwieser, D, Stegelmann, F, Schafhausen, P, Brümmendorf, T, Duyster, J, Blumenstengel, K, Scheid, C, Kneba, M, Kwong, Yl, Masszi, T, Petrini, M, Alimena, G, Di Raimondo, F, Rosti, G, Rotoli, B, Pane, Fabrizio, Pungolino, E, Amadori, S, Abruzzese, E, Fioritoni, G, Lauria, F, Bosi, A, Martelli, M, Rambaldi, A, Ferrara, F, Nobile, F, Gobbi, M, Carella, Am, Orlandi, Em, Leoni, P, Tiribelli, M, Levis, A, Imamura, M, Takahashi, N, Tsukamoto, N, Chiba, S, Nagai, T, Okamoto, S, Miura, O, Kurokawa, M, Ohnishi, K, Toba, K, Nakao, S, Tomita, A, Miyamura, K, Hino, M, Maeda, Y, Kimura, A, Kawaguchi, T, Miyazaki, Y, Nakaseko, C, Jinnai, I, Matsuda, A, Matsumura, I, Ishikawa, J, Ohyashiki, K, Okada, M, Usuki, K, Kobayashi, Y, Ohishi, K, Imai, K, Miyawaki, S, Kanda, Y, Park, Sy, Kim, Hj, Sohn, Sk, Lee, Kh, Jung, Cw, Ong, Tc, Gómez Almaguer, D, Kassack, J, Ossenkoppele, Gj, Gedde Dahl, T, Hjorth Hansen, H, Jedrzejczak, W, Dmoszynska, A, Starzak Dwozdz, J, Holowiecki, J, Kyrcz Krzemieñ, S, Kuliczkowski, K, Zaritsky, A, Turkina, A, Pospelova, T, Goh, Yt, Koh, Lp, Demitrovicova, L, Mistrik, M, Ruff, P, Louw, V, Dreosti, Lm, Novitzky, N, Cohen, G, Cervantes, F, Cañizo, C, de Paz, R, del Castillo, S, Perez Encinas, M, Sanz Alonso, M, Marin, F, Pérez López, R, Hernandez Boluda, J, Echeveste Gutierrez, Ma, Odriozola, J, Herrera, P, Steegman, Jl, Conde, E, Lopez, P, Giraldo, P, Boque, C, Heredia, B, Font, Aj, Rodriguez, Rf, Rodriguez, Mj, Batlle, J, Stenke, L, Lehmann, S, Wadenvik, H, Simonsson, B, Markevärn, B, Själander, A, Richter, J, Bjoreman, M, Eriksson, Km, Chalandon, Y, Shih, Ly, Yao, M, Wang, Mc, Jootar, S, Bunworasate, U, Ulkü, B, Haznedar, R, Undar, B, Sahin, B, Marin, D, Smith, G, Byrne, J, Holyoake, T, Kalaycio, M, Akard, L, Heaney, M, Al Janadi, A, Goldberg, S, Powell, B, Harker, Wg, Shea, T, Gingrich, R, Glass, J, Paquette, R, Siegrist, C, Woodson, M, Fehrenbacher, L, Koh, H, Flinn, I, Arrowsmith, E, Ervin, T, Guerra, M, Wallach, H, Berry, W, Burke, J, Edenfield, W, Guzley, G, Davis, J, Richards, D, Schlossman, D, Kolibaba, K, Alemany, C, Savin, M, Robbins, G, Lopez, J, Goldman, Jm, Camm, J, Schiffer, Ca, and Sargent, D. J.

Published
2010

47. Imatinib Discontinuation and Tki Switching Patterns in the Retrospective and Prospective Cohorts in Simplicity, A Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (PTS) in Routine Clinical Practice

Author

Zyczynski, T, primary, Khoury, J, additional, Goldberg, S, additional, Mauro, M, additional, Michallet, M, additional, Paquette, R, additional, Foreman, A, additional, Subar, M, additional, Turner, M, additional, Manley Daumont, M, additional, Hehlmann, R, additional, and Simonsson, B, additional

Published
2016
Full Text
View/download PDF

48. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Author

Hoffmann, V S, primary, Baccarani, M, additional, Hasford, J, additional, Castagnetti, F, additional, Di Raimondo, F, additional, Casado, L F, additional, Turkina, A, additional, Zackova, D, additional, Ossenkoppele, G, additional, Zaritskey, A, additional, Höglund, M, additional, Simonsson, B, additional, Indrak, K, additional, Sninska, Z, additional, Sacha, T, additional, Clark, R, additional, Bogdanovic, A, additional, Hellmann, A, additional, Griskevicius, L, additional, Schubert-Fritschle, G, additional, Sertic, D, additional, Guilhot, J, additional, Lejniece, S, additional, Zupan, I, additional, Burgstaller, S, additional, Koskenvesa, P, additional, Everaus, H, additional, Costeas, P, additional, Lindoerfer, D, additional, Rosti, G, additional, Saussele, S, additional, Hochhaus, A, additional, and Hehlmann, R, additional

Published
2016
Full Text
View/download PDF

49. Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: A preliminary report

Author

Gahrton, G., Björkholm, M., Brenning, G., Christenson, I., Engstedt, L., Franzén, S., Gullbring, B., Holm, G., Högman, C., Hörnsten, P., Jameson, S., Killander, A., Simonsson-Lindemalm, C., Lockner, D., Lönnqvist, B., Mellstedt, H., Palmblad, J., Paul, C., Pauli, C., Peterson, C., Reizenstein, P., Simonsson, B., Skårberg, K.-O., Udén, A.-M., and Wadman, B.

Published
1979
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results